Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca 2+ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity [1] [2] [3].
In Vivo, Eloralintide sodium (10-30 nmol/kg, s.c., single) activates AMYRs and CTR in rats, and induces a sustained decrease in plasma Ca2+ levels[1]. Eloralintide sodium (0.1-300 nmol/kg; s.c.; single dose) reduces food intake and body weight in lean rats, attenuates the induced conditioned taste aversion, and has an ED50 of 8.9 nmol/kg for reducing sweetener preference[3]. Eloralintide sodium (0.1-100 nmol/kg; s.c.; once every three days; 13 days) reduces food intake and body weight in male DIO rats by decreasing fat mass[3].
In Vitro, Eloralintide selectively activates AMY1R and AMY3R in UMUC3 cells expressing human or rat AMY1R, AMY3R or CTR, with an EC50 of 23.9 pM and a Ki of 478.1 pM for human AMY1R, an EC50 of 5.4 pM and a Ki of 48.1 pM for rat AMY1R, as well as an EC50 of 13.8 pM and a Ki of 161.0 pM for rat AMY3R[3].
References:
[1]. 86-OR_ The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels _ Diabetes _ American Diabetes Association.pdf
[2]. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643.
[3]. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271.
In Vivo, Eloralintide sodium (10-30 nmol/kg, s.c., single) activates AMYRs and CTR in rats, and induces a sustained decrease in plasma Ca2+ levels[1]. Eloralintide sodium (0.1-300 nmol/kg; s.c.; single dose) reduces food intake and body weight in lean rats, attenuates the induced conditioned taste aversion, and has an ED50 of 8.9 nmol/kg for reducing sweetener preference[3]. Eloralintide sodium (0.1-100 nmol/kg; s.c.; once every three days; 13 days) reduces food intake and body weight in male DIO rats by decreasing fat mass[3].
In Vitro, Eloralintide selectively activates AMY1R and AMY3R in UMUC3 cells expressing human or rat AMY1R, AMY3R or CTR, with an EC50 of 23.9 pM and a Ki of 478.1 pM for human AMY1R, an EC50 of 5.4 pM and a Ki of 48.1 pM for rat AMY1R, as well as an EC50 of 13.8 pM and a Ki of 161.0 pM for rat AMY3R[3].
References:
[1]. 86-OR_ The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels _ Diabetes _ American Diabetes Association.pdf
[2]. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643.
[3]. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271.